Shots:
- Scott gave a brief about the MedVector and shared his personal experience from his treatment of arthritis by participating in the clinical trial
- He also elaborated on how MedVector clarified the misunderstanding on FDA’s guidance on DCTs by the clinical research industry at the 41st Annual J.P. Morgan Health Care Conference 2023
- The interview depicts MedVector’s approach to empower clinical trial sites to efficiently gain access to more qualified clinical trial participants through treating physicians
Smriti: To start, could you please provide a brief bio to our readers about MedVector?
Scott Stout: MedVector is a clinical trial site-utility that allows community physicians to essentially “prescribe” a clinical trial as a care option and host select appointments from their local practice without becoming an investigator. The MedVector model eliminates concerns of patient leakage, giving investigators access to the missing-majority of patients otherwise trapped behind a treating physician that doesn’t refer to clinical trials. The result creates greater diversity and access to advanced medicine, allowing Pharma companies to save lives, faster.
Smriti: What inspired you to start the company and work to increase clinical trial access?
Scott Stout: In my mid 20’s I lost the ability to walk. My mother drove me from specialist to specialist trying to find a diagnosis. Without any success, I was finally admitted into the hospital where I met the specialist that changed my life. Within hours on the right medication I was walking again and within a month I had fully recovered.
I think often about how lucky I was to be in the right place at the right time. Why shouldn’t everyone have access to advanced medicine and clinical researchers like Dr. Orrin Troum? With MedVector, now they do.